itacitinib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

MPN (Myeloproliferative Neoplasms)

Conditions

MPN (Myeloproliferative Neoplasms)

Trial Timeline

Jul 16, 2012 → Jun 29, 2021

NCT ID

NCT01633372

About itacitinib

itacitinib is a phase 2 stage product being developed by Incyte for MPN (Myeloproliferative Neoplasms). The current trial status is completed. This product is registered under clinical trial identifier NCT01633372. Target conditions include MPN (Myeloproliferative Neoplasms).

What happened to similar drugs?

0 of 1 similar drugs in MPN (Myeloproliferative Neoplasms) were approved

Approved (0) Terminated (0) Active (1)

🔄Ruxolitinib + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05561985	Pre-clinical	Active	—	—	STAT1 Gain-of-Function Disease
NCT05823571	Phase 1	Active	Jul 6, 2023	Mar 1, 2030	Leukemia, Acute
NCT05063110	Phase 2	Completed	May 3, 2022	Oct 1, 2025	Adults Patients Having Non Severe HLH
NCT04629508	Phase 2	Completed	Jul 12, 2021	Aug 24, 2023	Myelofibrosis
NCT04640025	Phase 2	Active	Mar 10, 2021	Jun 22, 2026	Myelofibrosis
NCT04446182	Phase 2	Terminated	Jan 29, 2021	Jan 30, 2023	Chronic Graft-versus-host-disease
NCT04200365	Phase 2	Terminated	Jun 5, 2020	Sep 7, 2023	Chronic Graft-versus-host-disease
NCT03978637	Phase 1/2	Terminated	Feb 4, 2020	Oct 13, 2023	Bronchiolitis Obliterans Syndrome
NCT03670069	Phase 1	Terminated	Sep 30, 2019	May 6, 2024	Metastatic Leiomyosarcoma
NCT03755414	Phase 1	Completed	Sep 4, 2019	May 26, 2024	Acute Myelogenous Leukemia
NCT01633372	Phase 2	Completed	Jul 16, 2012	Jun 29, 2021	MPN (Myeloproliferative Neoplasms)

Competing Products

6 competing products in MPN (Myeloproliferative Neoplasms)

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib	Incyte	Phase 2	32
Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib	Incyte	Phase 2	24
Ruxolitinib + Anagrelide + Placebo + Placebo	Incyte	Phase 2	24
Ruxolitinib + Placebo	Incyte	Phase 3	37
Pemigatinib	Incyte	Phase 2	32
Itacitinib + Ruxolitinib	Incyte	Phase 2	32